Stephen Sabba Sells Shares of Ligand Pharmaceuticals

On June 16, 2026, Stephen Sabba sold 2,145 shares of Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND). The transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Ligand Pharmaceuticals Incorporated

Stephen Sabba executed a sale of 2,145 shares at an unspecified price on June 16, 2026. This sale was not made under a Rule 10b5-1 plan. Earlier, on the same day, he had acquired the same number of shares at $66.13 each. Another insider, Jason Haas, sold 6,461 shares on June 12, 2026, at an average price of $255.58, following a purchase of 4,000 shares at $51.56.

Other Institutional Activity in Ligand Pharmaceuticals

BlackRock, Inc. increased its holdings by 21,692 shares, reaching a total of 2,961,923 shares valued at approximately $591.35 million. Vanguard Portfolio Management LLC took a new position with 1,100,267 shares worth about $219.67 million. Janus Henderson Group PLC added 14,491 shares, bringing its total to 1,009,891 shares valued at $201.62 million. Invesco Ltd. significantly boosted its stake by 307,140 shares, ending with 823,604 shares valued at $164.43 million.

Ligand Pharmaceuticals Stock Snapshot

Shares of Ligand Pharmaceuticals are trading near $264.41. The company has a market cap of $5.27 billion with a P/E ratio of 34.31 and a forward P/E of 23.25. The stock's beta is 1.039, indicating moderate volatility. Over the past year, the stock has ranged from a low of $110.00 to a high of $267.27. Its 50-day moving average is $229.40, and its 200-day moving average is $200.85. The company maintains a robust current ratio of 21.28 and a quick ratio of 20.81, with a debt-to-equity ratio of 45.32.

Recent Earnings

Ligand Pharmaceuticals reported revenue of $274.48 million, showing a growth of 14.1%. The net margin stands at 55.95%, with a return on equity of 17.13%. Earnings per share were $7.67. The next earnings report is expected on August 6, 2026.

Analysts Set New Price Targets

On May 8, 2026, RBC Capital maintained its "buy" rating on Ligand Pharmaceuticals with a price target of $262.00. Earlier, on April 30, 2026, HC Wainwright & Co. also maintained a "buy" rating with a target of $289.00. Citigroup has consistently maintained a "buy" rating, setting a target of $282.00 on April 15, 2026. The consensus among analysts suggests a mean price target of $277.60, with 10 analysts currently offering opinions.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company based in Jupiter, Florida. It develops and licenses various biopharmaceutical assets worldwide. The company offers treatments for infectious diseases, multiple myeloma, osteoporosis, and more. Led by CEO Todd C. Davis, Ph.D., Ligand employs 47 people and operates within the healthcare sector, focusing on biotechnology.

Bottom Line

Stephen Sabba's recent sale of Ligand Pharmaceuticals shares is part of regular insider activity. Investors often watch insider transactions to gauge market sentiment. Ligand's stock remains well-regarded, with steady institutional interest and positive analyst ratings. Remember, insider trades are backward-looking and may not reflect current positions.